The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.

<h4>Background</h4>Because of the potentially significant economic burden of healthcare costs associated with many diseases, it is critical that regulatory and medical insurance organisations collect and utilise data on the cost-effectiveness of care provision to make rational policy dec...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaohui Zeng, Jonathan Karnon, Siying Wang, Bin Wu, Xiaomin Wan, Liubao Peng
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/61b7172900c44d00bd6102368b0ea5af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:61b7172900c44d00bd6102368b0ea5af
record_format	dspace
spelling	oai:doaj.org-article:61b7172900c44d00bd6102368b0ea5af2021-11-18T08:10:26ZThe cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.1932-620310.1371/journal.pone.0048323https://doaj.org/article/61b7172900c44d00bd6102368b0ea5af2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23118985/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Because of the potentially significant economic burden of healthcare costs associated with many diseases, it is critical that regulatory and medical insurance organisations collect and utilise data on the cost-effectiveness of care provision to make rational policy decisions. However, little is known about healthcare costs in China.<h4>Methodology/principal findings</h4>Based on health expenditure data for 253 cases of advanced non-small cell lung cancer (NSCLC) registered at the Second Xiangya Hospital of Central South University in China between 2006 and 2010, the cost of care provision was analysed. The monthly and aggregate annual medical costs were estimated for patients who were in either a progression-free state (PFS) or a disease-progression state (DPS). Monthly healthcare costs accumulated during the terminal 3 months were collected separately. The mean cost of treatment for PFS and DPS patients over one year was approximately US$11,566 and $14,519, respectively. The monthly costs for all patients were higher initially than in the subsequent months (PFS: $2,490; DPS: $2,503). For PFS patients, healthcare expenditures stabilised after the 7th month, with a mean monthly medical expenditure of $82.49. For DPS patients, expenditures stabilised after the 9th month, and the mean expenditure during the 9th month was $307.9. Medical care costs in the three successive months prior to death were $3,754, $5,829 and $7,372, respectively.<h4>Conclusions/significance</h4>The economic evaluation of health care technologies is becoming ever more important in China, especially in disease areas for which new and expensive therapies are being introduced on a regular basis. This is first paper to present empirically estimated China-specific costs associated with the treatment of NSCLC. The cost estimates are presented in a format that is specifically intended to inform cost-effectiveness analyses of treatments for NSCLC, and hence, contribute to the more efficient allocation of limited healthcare resources in China.Xiaohui ZengJonathan KarnonSiying WangBin WuXiaomin WanLiubao PengPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 10, p e48323 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xiaohui Zeng Jonathan Karnon Siying Wang Bin Wu Xiaomin Wan Liubao Peng The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.
description	<h4>Background</h4>Because of the potentially significant economic burden of healthcare costs associated with many diseases, it is critical that regulatory and medical insurance organisations collect and utilise data on the cost-effectiveness of care provision to make rational policy decisions. However, little is known about healthcare costs in China.<h4>Methodology/principal findings</h4>Based on health expenditure data for 253 cases of advanced non-small cell lung cancer (NSCLC) registered at the Second Xiangya Hospital of Central South University in China between 2006 and 2010, the cost of care provision was analysed. The monthly and aggregate annual medical costs were estimated for patients who were in either a progression-free state (PFS) or a disease-progression state (DPS). Monthly healthcare costs accumulated during the terminal 3 months were collected separately. The mean cost of treatment for PFS and DPS patients over one year was approximately US$11,566 and $14,519, respectively. The monthly costs for all patients were higher initially than in the subsequent months (PFS: $2,490; DPS: $2,503). For PFS patients, healthcare expenditures stabilised after the 7th month, with a mean monthly medical expenditure of $82.49. For DPS patients, expenditures stabilised after the 9th month, and the mean expenditure during the 9th month was $307.9. Medical care costs in the three successive months prior to death were $3,754, $5,829 and $7,372, respectively.<h4>Conclusions/significance</h4>The economic evaluation of health care technologies is becoming ever more important in China, especially in disease areas for which new and expensive therapies are being introduced on a regular basis. This is first paper to present empirically estimated China-specific costs associated with the treatment of NSCLC. The cost estimates are presented in a format that is specifically intended to inform cost-effectiveness analyses of treatments for NSCLC, and hence, contribute to the more efficient allocation of limited healthcare resources in China.
format	article
author	Xiaohui Zeng Jonathan Karnon Siying Wang Bin Wu Xiaomin Wan Liubao Peng
author_facet	Xiaohui Zeng Jonathan Karnon Siying Wang Bin Wu Xiaomin Wan Liubao Peng
author_sort	Xiaohui Zeng
title	The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.
title_short	The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.
title_full	The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.
title_fullStr	The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.
title_full_unstemmed	The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.
title_sort	cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/61b7172900c44d00bd6102368b0ea5af
work_keys_str_mv	AT xiaohuizeng thecostoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience AT jonathankarnon thecostoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience AT siyingwang thecostoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience AT binwu thecostoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience AT xiaominwan thecostoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience AT liubaopeng thecostoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience AT xiaohuizeng costoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience AT jonathankarnon costoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience AT siyingwang costoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience AT binwu costoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience AT xiaominwan costoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience AT liubaopeng costoftreatingadvancednonsmallcelllungcancerestimatesfromthechineseexperience
_version_	1718422109154181120

The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.

Ejemplares similares